Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Substance-Related Disorders

In brief

This is a single site, double-blind, randomized, placebo-controlled, crossover study to assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy, opioid-experienced, non-treatment-seeking subjects.

Key facts

Study ID
NCT01046539
Run by
National Institute on Drug Abuse (NIDA)
People needed
12
Starts
2010-01-01
Expected to finish
2010-07-01
Last updated by the study team
2017-01-11

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.